Research programme: cancer therapy - BiovitrumAlternative Names: BVT 51004
Latest Information Update: 05 Jun 2007
At a glance
- Originator Biovitrum
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Jun 2007 Discontinued - Preclinical for Cancer in Sweden (unspecified route)
- 24 Aug 2005 Preclinical trials in Cancer in Sweden (unspecified route)